Quantitation of human immunodeficiency virus type 1 group O load in plasma by measuring reverse transcriptase activity.

Journal of clinical microbiology

PubMedID: 10618125

García Lerma JG, Soriano V, Mas A, Quiñones-Mateu ME, Arts EJ, Heneine W. Quantitation of human immunodeficiency virus type 1 group O load in plasma by measuring reverse transcriptase activity. J Clin Microbiol. 2000;38(1):402-5.
We have evaluated the use of an ultrasensitive reverse transcriptase (RT) activity assay to monitor plasma viremia in two human immunodeficiency virus type 1 (HIV-1) group O-infected patients treated with stavudine, lamivudine, and indinavir. After a initial decline in RT levels observed at 4 weeks of therapy, RT-based plasma viremia returned to baseline values at 28 or 44 weeks of treatment. The rebound in levels of RT activity was associated with the detection of phenotypic resistance to lamivudine and with the Met184Val mutation. Analysis of RT activity in plasma provides a sequence-independent means of monitoring virus loads in HIV-1 group O-infected patients.